Click a year to reveal what happened.
Great journeys begin with a single step. Unistar Biotech Limited was founded by a group of bright minds united by a single purpose: serving humanity through excellence in healthcare.
We commenced operations in Jharkhand and Delhi-NCR.
Expanded our footprint by commencing operations in Jammu & Kashmir.
Strengthened our presence across Bihar, Jharkhand, and Delhi-NCR, reinforcing our market foundation along with wider reach to new Hqs.
After strengthening our presence in Bihar, Jharkhand, and Delhi-NCR, we expanded our footprint by commencing operations in Odisha.
Strengthened our presence in Orthopaedics and Gastroenterology through the successful launch of ASPIRA TH-4, ASPIRA TH-8, ANXURIDE-25, and ANXURIDE-50..
Achieved a significant growth milestone with a year-on-year growth rate exceeding 46%.
Achieved a major milestone with the launch of our flagship brand, Nervistar CD-3, driving the next phase of growth.
Consolidated our presence across Bihar, Jharkhand, and Odisha, strengthening our regional footprint and market reach.
Achieved sustained double-digit growth across the year compared to the previous year, setting a new benchmark for performance.
Demonstrated unwavering commitment during the COVID-19 crisis by supplying N-95 masks and PPE kits to frontline workers and communities in need.
Strengthened our regional presence by launching operations in Chhattisgarh and West Bengal, signalling a strong comeback and renewed growth.
Launched the Montliza, Torlept, and Tolprez brand groups, marking a significant expansion of our product portfolio.
Proudly sponsored the prestigious IACMCON conference at Rajgir, reinforcing our commitment to the medical fraternity and industry engagement.
Expanded our team and strengthened our presence across Bihar, Jharkhand, Odisha, and Chhattisgarh, while successfully launching operations in Rajasthan.
Achieved a YPM of ₹1.25 Crore while expanding into Urology with the launch of Prostolin and Prostolin-D, marking a new chapter in our growth journey.
Continued our growth momentum through the expansion of our Gastroenterology segment and the successful launch of Vonprazin